Evidence map›Paper›PMID 39157750›Full record

ArticleFarmaceuticos comunitarios2024

[Probable pharmacological interaction between sulfonylurea and beta-blocker in a patient with DM-II. A case report].

Gregoreo Centeno-Hoil, Homa Mousavi

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in Farmaceuticos comunitarios, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gregoreo Centeno-HoilFarmacéutico comunitario. Farmacia Zarzuelo, Benalmádena (Málaga). Farmacia España.
Homa MousaviFarmacéutico comunitario. Farmacia Zarzuelo, Benalmádena (Málaga). Farmacia España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study presents the case of a 47-year-old woman with type 2 diabetes (T2D), hypertension and anemia, treated with metformin, glyburide, metoprolol, and iron/folic acid. A drug interaction was identified between glyburide and metoprolol, causing symptoms of hypoglycemia in the afternoon. Evaluation using Horn's Drug Interaction Probability Scale (DIPS) suggested a probable interaction. Pharmacokinetic analysis revealed that the time at which the maximum concentrations of both drugs were reached coincided with the onset of symptoms. A new medication schedule was implemented which resolved the symptoms. The drug interaction was attributed to the blockade of adrenergic effects by metoprolol, compromising the ability to counteract the action of insulin released by glybenclamide. The importance of surveillance, informed decision-making and the implementation of preventive strategies is highlighted to ensure the safety and effectiveness of pharmacological treatment in patients with specific clinical conditions, such as T2D and concomitant cardiovascular diseases.

Indexed as

Diabetes Mellitus, Type 2Drug InteractionsHypoglycemic AgentsMetoprololAdrenergic beta-AntagonistsFemaleGlyburideHumansHypertensionHypoglycemiaMiddle AgedSulfonylurea CompoundsAdrenergic beta-AntagonistsGlyburideHypoglycemic AgentsMetoprololSulfonylurea CompoundsDiabetes Mellitus type 2Drug InteractionsGlybenclamideHypoglycemiaMetoprolol

Identifiers

PMID39157750
PMCPMC11328701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.